SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 4366.
  • 2
    Ramalingam S,Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol. 2004; 31: 6874.
  • 3
    Schiller JH,Harrington D,Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 4
    Kelly K,Crowley J,Bunn PAJr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. JClin Oncol. 2001; 19: 3210328.
  • 5
    Treat J,Belani CP,Edelman M,Socinski MA,Ansari R. A randomized phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in advanced non-small cell lung cancer: update of the Alpha Oncology Trial [abstract]. J Clin Oncol. 2005; 23: 1096. Abstract 7025.
  • 6
    Smit EF,van Meerbeeck JP,Lianes P, et al. Three-arm randomized study of 2 cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. J Clin Oncol. 2003; 21: 39093917.
  • 7
    Baselga J. The EGFR as a target for anticancer therapy—focus on cetuximab. Eur J Cancer. 2001; 37( suppl 4): S1622.
  • 8
    Baselga J,Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep. 2002; 4: 317324.
  • 9
    Kurai J,Chikumi H,Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007; 13: 15521561.
  • 10
    Hanna N,Lilenbaum R,Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006; 24: 5253528.
  • 11
    Nakata E,Hunter N,Mason K,Fan Z,Ang KK,Milas L. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2004; 59: 11631173.
  • 12
    Morelli MP,Cascone T,Troiani T, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16( suppl 4): iv61iv8.
  • 13
    Baselga J,Norton L,Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993; 85: 13271333.
  • 14
    Baselga J,Pfister D,Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18: 904914.
  • 15
    Fossella F,Pereira JR,von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003; 21: 30163024.
  • 16
    Calvert AH,Newell DR,Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7: 17481756.
  • 17
    Therasse P,Arbuck SG,Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 18
    Rosell R,Daniel C,Ramlau R,Szczesna A,Constenla M,Mennecier B. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2004; 23: 618.
  • 19
    Thienelt CD,Bunn PAJr,Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005; 23: 87868793.
  • 20
    Robert F,Blumenschein G,Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23: 90899096.
  • 21
    Giaccone G,Herbst RS,Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. JClin Oncol. 2004; 22: 777784.
  • 22
    Herbst RS,Giaccone G,Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol. 2004; 22: 785794.
  • 23
    Butts C,Bodkin D,Middleman E, et al. Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer [abstract]. J Clin Oncol. 2007; 25: 394s. Abstract 7539.
  • 24
    Lynch T,Patel T,Dreisbach L, et al. A randomized phase III study of cetuximab in combination with taxane/carboplatin verus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer [abstract]. J Thorac Oncol. 2007; 2: S340. Abstract B3-03.
  • 25
    Pirker R,Szczesna A,Von Pawel J, et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine verus cisplatin/vinorelbine alone in the first-line treatment of patients with advanced non-small cell lung cancer [abstract]. J Clin Oncol. 2008; 26: 6s. Abstract 3.
  • 26
    Herbst RS,Chansky K,Kelly K, et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342 [abstract]. J Clin Oncol. 2007; 25: 395s. Abstract 7545.
  • 27
    Paez JG,Janne PA,Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 14971500.